Kelly Dunst on 02 4, 2012 | No Comments
IBM (NYSE: IBM) has been selected for a global research project to develop the world’s first integrated environmental monitoring system aimed at helping oil and gas companies minimize the environmen
Read MoreKelly Dunst on 02 4, 2012 | No Comments
The Drugs for Neglected Diseases initiative (DNDi) and Abbott (NYSE: ABT) have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for sever
Read MoreKelly Dunst on 02 4, 2012 | No Comments
Pfizer Inc. today issued the following statement regarding the voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol): “We have announced a voluntary recall of Lo/Ovral®-28 (norges
Read MoreKelly Dunst on 02 4, 2012 | No Comments
13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to ac
Read MoreKelly Dunst on 02 1, 2012 | No Comments
From Design to Delivery, SAP® Solutions Helps Leading Medical Device Manufacturer With Significant Savings, Revenue Protection and Return on Investment With increasing public scrutiny and regulati
Read MoreKelly Dunst on 02 1, 2012 | No Comments
GE Capital and GE Healthcare, the financial services and healthcare divisions of General Electric Company (NYSE: GE), announced today an investment in Check-Cap, Ltd., a developer of an ingestible ima
Read MoreKelly Dunst on 01 27, 2012 | No Comments
Roche today announced a grant to the Albert Einstein College of Medicine of Yeshiva University in New York City, which will be used for the establishment of a program to improve basic cancer care in E
Read MoreKelly Dunst on 01 27, 2012 | No Comments
Optum, a leading health services company, is offering a free emotional-support help line for people in Alabama affected by the recent tornados. The company’s toll-free help line number, 866-342-6
Read MoreKelly Dunst on 01 27, 2012 | No Comments
Depomed, Inc. (Nasdaq:DEPO) today announced that it has initiated a Phase 2 clinical trial of DM-1992, Depomed's novel gastric-retentive, extended-release formulation of carbidopa/levodopa, in patient
Read MoreKelly Dunst on 01 27, 2012 | No Comments
Depomed, Inc. (Nasdaq:DEPO) today announced that it has received a Paragraph IV certification notice from Actavis Elizabeth LLC advising Depomed that Actavis has filed an Abbreviated New Drug Applicat
Read More